Professor of Medicine, University Tex Houston
Oncology
Dr. Merrill S. Kies, MD
|
|
Give Review
Doctor Merrill S. Kies, MD is an expert in the field of Oncology. He attended Loyola University Chicago Stritch School of Medicine. He received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Super Doctor". Merrill Kies is a published doctor and has 83 publications published. The lastest was: 'Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.' Merrill Kies accepts Medicare.
Publications
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic Carcinoma and for nonadenoid cystic malignant salivary tumors.
- Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
- Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic Carcinoma: A series of 9 cases and a critical review of the ...
- Merkel Cell carcinoma of the head and neck: Favorable outcomes with radiotherapy.
- Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients.
- Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
- Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma (SDC) of Both Sexes: Potential Therapeutic Ramifications.
- Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234.
- Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice.
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous Cell carcinoma of the head and ...
- A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers.
- Prognostic Factors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma.
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced Cancer.
- Head and Neck Cancers, Version 2.2013.
- Detailed Genome-Wide SNP Analysis of Major Salivary Carcinomas Localizes Subtype-Specific Chromosome Sites and Oncogenes of Potential Clinical Significance.
- Outcomes and patterns of care of patients with locally advanced oropharyngeal Carcinoma treated in the early 21st century.
- Residual nodal disease in patients with advanced-stage oropharyngeal squamous Cell carcinoma treated with definitive radiation therapy and posttreatment neck dissectio...
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous Cell carcinoma of the head and neck.
- Prognostic factors in mucoepidermoid carcinoma of the salivary Glands.
- Concurrent chemoradiation for adenoid cystic Carcinoma of the head and neck.
- Phase II trial of induction chemotherapy followed by surgery for squamous Cell carcinoma of the oral tongue in young adults.
- Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma.
- Head and neck Cancers.
- To TORS or Not to TORS: but is that the question? Comment on "transoral robotic surgery for advanced oropharyngeal Carcinoma".
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell Cancer.
- Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung Cancer.
- Genetic and expression analysis of HER-2 and EGFR genes in salivary duct Carcinoma: empirical and therapeutic significance.
- Induction chemotherapy and cetuximab for locally advanced squamous Cell carcinoma of the head and neck: results from a phase II prospective trial.
- A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous Cell carcinoma of the head and neck.
- Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue Cancer.
- Durable long-term remission with chemotherapy alone for stage II to IV laryngeal Cancer.
- The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.
- Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck Cancer.
- Evaluation and management of the unknown primary Carcinoma of the head and neck.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid Cancer: results from a phase II study.
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- Quantitative promoter hypermethylation analysis of cancer-related genes in salivary Gland carcinomas: comparison with methylation-specific PCR technique and clinical s...
- Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and n...
- Videos in clinical medicine. Examination of the larynx and pharynx.
- Differential expression of hormonal and growth factor receptors in salivary duct Carcinomas: biologic significance and potential role in therapeutic stratification of ...
- Measuring head and neck Cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.
- Quality of life in head and neck Cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
- Induction chemotherapy for head and neck squamous Cell carcinomas (SCCHN).
- Induction chemotherapy for squamous Cancer of the head and neck.
- Implications of methylation patterns of cancer genes in salivary Gland tumors.
- Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced Cancer.
- Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell Cancer of the head and neck.
- High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous Cell carcinoma of the head and neck treated in a multicenter pha...
- Merkel Cell carcinoma of the tongue and head and neck oral mucosal sites.
- Phase II trial of taxol in salivary Gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
- Asian ethnicity as a predictor of response in patients with non-small-cell lung Cancer treated with gefitinib on an expanded access program.
- Radiotherapy plus cetuximab for squamous-Cell carcinoma of the head and neck.
- Postoperative treatment intensification for improving outcome in the high-risk patient: an evolutionary process.
- Neoadjuvant chemotherapy for squamous Cell carcinoma of the oral tongue in young adults: a case series.
- Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous Cell carcinoma of the head an...
- Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid Tumors: pharmacokinetic and clinical results.
- Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall Cell lung carcinoma.
- Differential expression of p63 isotypes (DeltaN and TA) in salivary Gland neoplasms: biological and diagnostic implications.
- New treatments in head and neck Cancer.
- Sinonasal malignancies with Neuroendocrine differentiation: patterns of failure according to histologic phenotype.
- Head and neck Cancer: integrating anti-EGFR treatment with standard therapy.
- Radiation-induced xerostomia in patients with head and neck Cancer: pathogenesis, impact on quality of life, and management.
- Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck Cancer.
- Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid Tumors.
- Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung Cancer: report of a randomized comparative trial.
- Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck Carcinoma?
- Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck Cancer treated with chemoradiotherapy.
- Cetuximab in Cancers of the lung and head & neck.
- Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus Carcinoma.
- Gefitinib: current and future status in Cancer therapy.
- Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin ...
- Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanc...
- Intensive concurrent chemoradiotherapy for head and neck Cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
- Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall Cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
- Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous Cell carcinoma of the head and ...
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall Cell lung carcinoma: potential for decreased toxicity an...
- An exploration of the pretreatment coping strategies of patients with Carcinoma of the head and neck.
- Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung Cancer.
- Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate Cancer.
- ZD1839 (Iressa) in non-small cell lung Cancer.
- MicroRNA Profiling of Salivary Adenoid Cystic Carcinoma: Association of miR-17-92 Upregulation with Poor Outcome.
Schools
Loyola Univ Of Chicago Stritch Sch Of Med
Walter Reed Army Med Center
Brook Army Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Super Doctor
Education
-
San Antonio Uniformed Services Health Education Consortium -
Loyola University Chicago Stritch School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1972694917 | |
| NPPES Provider LastName | KIES | |
| NPPES Provider FirstName | MERRILL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 431.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 70.0 | |
| Percent Opioid Claims | 16.24 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972694917 |
| Last Name Of The Provider | KIES |
| First Name Of The Provider | MERRILL |
| View All |
Similar Doctors
|
Dr. Garth A. Beinart, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna M. Weber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Zarzour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eduardo D. Bruera, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Uzma Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. L A. Nazario, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Philip A. Salem, MD
This Doctor is OpenDoctor Recommended.
|